Alkermes Plc
NASDAQ:ALKS

Watchlist Manager
Alkermes Plc Logo
Alkermes Plc
NASDAQ:ALKS
Watchlist
Price: 28.78 USD 3.9% Market Closed
Market Cap: 4.7B USD
Have any thoughts about
Alkermes Plc?
Write Note

Gross Margin
Alkermes Plc

83.2%
Current
83%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
83.2%
=
Gross Profit
1.3B
/
Revenue
1.5B

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
IE
Alkermes Plc
NASDAQ:ALKS
4.7B USD
83%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
312.7B USD
67%
US
Amgen Inc
NASDAQ:AMGN
158.3B USD
60%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD
86%
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD
78%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
133.6B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
34.5B EUR
89%
Country IE
Market Cap 4.7B USD
Gross Margin
83%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 312.7B USD
Gross Margin
67%
Country US
Market Cap 158.3B USD
Gross Margin
60%
Country US
Market Cap 115.9B USD
Gross Margin
86%
Country US
Market Cap 112.4B USD
Gross Margin
78%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 133.6B AUD
Gross Margin
52%
Country US
Market Cap 82.6B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 34.5B EUR
Gross Margin
89%
No Stocks Found

Alkermes Plc
Glance View

Market Cap
4.7B USD
Industry
Biotechnology

Alkermes Plc is a global biopharmaceutical company. The company is headquartered in Dublin, Dublin and currently employs 2,211 full-time employees. The firm is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The company has a portfolio of commercial products focused on addiction, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. The firm's products include ALKERMES, ARISTADA, ARISTADA INITIO, LinkeRx, LYBALVI, NanoCrystal and VIVITROL. Its other trademark includes INVEGA SUSTENNA, INVEGA TRINZA, TREVICTA, XEPLION, and RISPERDAL CONSTA, KEYTRUDA and VUMERITY. The firm's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

ALKS Intrinsic Value
28.59 USD
Overvaluation 1%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
83.2%
=
Gross Profit
1.3B
/
Revenue
1.5B
What is the Gross Margin of Alkermes Plc?

Based on Alkermes Plc's most recent financial statements, the company has Gross Margin of 83.2%.